RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:First Patient Dosed in Phase 1 Trial of TH1902 Presumably all the patients or so in Ph1 part1 will be giving blood hourly or so over six hours or so for the PK work, I'd agree that's going to be important very early data. What you're ignoring here is that most is likely pee'd out of the body. It will definitely be great to see the curves in column 4 of this poster in mice be followed by a similar path in humans. But I don't think that confirms anything about efficacy, it tells us about one potential path to toxicity.
https://www.theratech.com/wp-content/uploads/2019/12/SABCS_2019.pdf
jfm1330 wrote: I almost doubled my position today. Strange to see the SP fall on such a news.
Looking at the trial protocol on clinicaltrials.gov, I noticed an important aspect that will give the scientists involved in the trial a very early indication to know if the PDC works as intended, at least to bond with receptors. They will monitor free docetaxel in the blood after injection. If they find almost nothing, it will be a good indication that the PDC is stable in the bloodstream and that it bonds with sortilin and introduced inside the cells bearing this receptor. They will also do dosing of TH1902 in the blood (PK profile). So I think that well before safety data, they will know if the PDC (TH1902) is working as planned as far as not staying in the bloostream intil enzymatic degradation. Proof of releasing free docetaxel into cancer cells is another story. But the proof that it is not degraded in the bloodstream would be a very good first step towards proof of efficacy.